Entrada Historical Cash Flow
| TRDA Stock | USD 19.37 0.33 1.73% |
Analysis of Entrada Therapeutics cash flow over time is an excellent tool to project Entrada Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 93.3 M or Other Cashflows From Financing Activities of 1.5 M as it is a great indicator of Entrada Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Entrada Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Entrada Therapeutics is a good buy for the upcoming year.
Entrada |
About Entrada Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Entrada balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Entrada's non-liquid assets can be easily converted into cash.
Entrada Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Entrada Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Entrada Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Entrada Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Entrada Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.At present, Entrada Therapeutics' Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 13.8 M, whereas Investments are projected to grow to (131.7 M).
| 2022 | 2023 | 2024 (projected) | Sale Purchase Of Stock | 284K | 443K | 420.9K | Change To Liabilities | 5.3M | 6.1M | 6.4M |
Entrada Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Entrada Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.